Citi lowered the firm’s price target on Danaher (DHR) to $265 from $285 and keeps a Buy rating on the shares post the Q4 report. The company guided below expectations, the analyst tells investors in a research note. The firm says that while management is typically conservative, the initial earnings outlook is lower than anticipated with a ramp throughout 2025, though it believes the bioprocessing guide has upside given consumables momentum.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $240 from $275 at Barclays
- Danaher Corporation Reports Steady 2024 Financial Performance
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher price target lowered to $240 from $250 at Goldman Sachs
- Danaher price target lowered to $260 from $285 at Jefferies